search
Back to results

Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy

Primary Purpose

Cerebral Palsy

Status
Recruiting
Phase
Phase 2
Locations
Russian Federation
Study Type
Interventional
Intervention
CP CB-MNC injection
Standard therapy
Sponsored by
State-Financed Health Facility "Samara Regional Medical Center Dinasty"
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cerebral Palsy focused on measuring Cerebral palsy, CP, Cord Blood, Stem cells

Eligibility Criteria

1 Year - 10 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- Confirmed diagnosis: Cerebral Palsy.

Exclusion Criteria:

  • the presence of the following diseases in history: heart failure in the stage of decompensation, stroke in history less than 1 year ago, blood diseases;
  • decompensation of chronic and endocrinological diseases;
  • acute respiratory viral and bacterial infections, period less than 1 month after the acute phase.
  • HIV infection, hepatitis B and C.
  • oncological diseases, chemotherapy in the anamnesis;
  • tuberculosis.

Sites / Locations

  • Medical Centre DinastyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

CP CB-MNC injection

Standard therapy

Arm Description

CP CB-MNC injection from different donors and standard therapy.

Patients with standard therapy as control group

Outcomes

Primary Outcome Measures

Number of participants with non-serious and serious adverse events
Safety assessment such as adverse events will be registered. Adverse events will be monitored during all trial.
Changes in Standardized Gross Motor Function 66 (GMFM-66) Score for all child.
GMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of sub-scales; lying & rolling, sitting, crawling & kneeling, standing, walking, running & jumping (range: 0~100 , Higher value means better gross motor function). We reported changes of GMFM between each assessment time points. Categories of outcome table are baseline and values of just subtracting the latter raw scores from the former ones. This test will be acquired for all child.
Changes in Cognitive Neurodevelopmental Outcome for child before 3yrs
Bayley Scale of Infant Development-II (K-BSID-II) Mental Scales (higher value means better mental function: 0 - worst, 178 - best). We reported changes of BSID-II Mental Scale raw score between each assessment time points. Categories of outcome data are values of subtracting the latter scores from the former ones.This test will be acquired for child before 3yrs.
Changes in The Infant Toddler Quality of Life Questionnaire for child above 3yrs.
ITQOL - the 47-item short-form (ITQOL-SF47) developed for use in infants and toddlers from 2-months-to-5 years of age. Form scores physical, mental and social well being/ For each concept, item responses are scored, summed, and transformed on a scale from 0 (worst health) to 100 (best health). Changes in completed questionnaire will be assessed. This test will be acquired for child above 3yrs.
Changes in Ashworth scale score for all child.
The Ashworth scale (AS) measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity scoring, where: 0 No increase in tone; Slight increase in tone giving catch when the limb is moved in flexion and extension; More marked increase in tone, but limb is easily flexed; Considerable increases in tone, passive movement difficult; Limb rigid in flexion or extension. This test will be acquired for child above 3yrs.

Secondary Outcome Measures

Number of Participants with Chimerism (longevity) of infused cell
Chimerism study to detect the longevity of infused donor cells and predict effectiveness of treatment. This study measure DNA of donor cells will in patients blood at the end of protocol. Absence of donor DNA suggest no chimerism.

Full Information

First Posted
January 22, 2019
Last Updated
January 17, 2023
Sponsor
State-Financed Health Facility "Samara Regional Medical Center Dinasty"
search

1. Study Identification

Unique Protocol Identification Number
NCT03826498
Brief Title
Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy
Official Title
Efficiency Evaluation of Allogenic Umbilical Cord Blood Mononuclear Cells (UCB-MNC) Transfusion in Patients With Autism
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 12, 2018 (Actual)
Primary Completion Date
January 26, 2024 (Anticipated)
Study Completion Date
December 26, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
State-Financed Health Facility "Samara Regional Medical Center Dinasty"

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Cerebral palsy is a disorder of movement and posture resulted from a non-progressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability. Many experimental animal studies have revealed that umbilical cord blood is useful to repair neurological injury in brain. On the basis of many experimental studies, umbilical cord blood is suggested as a potential therapy for cerebral palsy.
Detailed Description
Cerebral palsy (CP) is a group of neurodevelopmental conditions with abnormal movement and posture resulted from a non-progressive cerebral disturbance. It is the most common cause of motor disability in childhood. Most therapies are palliative rather than restorative. Umbilical cord blood (UCB) may be used as restorative approach for children with CP. Many experimental animal studies have revealed that UCB is beneficial to improve and repair neurological injuries, this effect achieved due to immune regulation and angiogenesis as well as the neuroprotective effect. Based on animal studies and some clinical trials, UCB is suggested as a potential therapy for children with CP. This study is prospective, non randomized (open label) with control group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebral Palsy
Keywords
Cerebral palsy, CP, Cord Blood, Stem cells

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CP CB-MNC injection
Arm Type
Experimental
Arm Description
CP CB-MNC injection from different donors and standard therapy.
Arm Title
Standard therapy
Arm Type
Other
Arm Description
Patients with standard therapy as control group
Intervention Type
Biological
Intervention Name(s)
CP CB-MNC injection
Intervention Description
CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
Intervention Type
Other
Intervention Name(s)
Standard therapy
Intervention Description
The standard therapy can include drugs, special psychology training etc.
Primary Outcome Measure Information:
Title
Number of participants with non-serious and serious adverse events
Description
Safety assessment such as adverse events will be registered. Adverse events will be monitored during all trial.
Time Frame
6 month
Title
Changes in Standardized Gross Motor Function 66 (GMFM-66) Score for all child.
Description
GMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of sub-scales; lying & rolling, sitting, crawling & kneeling, standing, walking, running & jumping (range: 0~100 , Higher value means better gross motor function). We reported changes of GMFM between each assessment time points. Categories of outcome table are baseline and values of just subtracting the latter raw scores from the former ones. This test will be acquired for all child.
Time Frame
1, 3, 6 month
Title
Changes in Cognitive Neurodevelopmental Outcome for child before 3yrs
Description
Bayley Scale of Infant Development-II (K-BSID-II) Mental Scales (higher value means better mental function: 0 - worst, 178 - best). We reported changes of BSID-II Mental Scale raw score between each assessment time points. Categories of outcome data are values of subtracting the latter scores from the former ones.This test will be acquired for child before 3yrs.
Time Frame
1, 3, 6 month
Title
Changes in The Infant Toddler Quality of Life Questionnaire for child above 3yrs.
Description
ITQOL - the 47-item short-form (ITQOL-SF47) developed for use in infants and toddlers from 2-months-to-5 years of age. Form scores physical, mental and social well being/ For each concept, item responses are scored, summed, and transformed on a scale from 0 (worst health) to 100 (best health). Changes in completed questionnaire will be assessed. This test will be acquired for child above 3yrs.
Time Frame
1, 3, 6 month
Title
Changes in Ashworth scale score for all child.
Description
The Ashworth scale (AS) measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity scoring, where: 0 No increase in tone; Slight increase in tone giving catch when the limb is moved in flexion and extension; More marked increase in tone, but limb is easily flexed; Considerable increases in tone, passive movement difficult; Limb rigid in flexion or extension. This test will be acquired for child above 3yrs.
Time Frame
1, 3, 6 month
Secondary Outcome Measure Information:
Title
Number of Participants with Chimerism (longevity) of infused cell
Description
Chimerism study to detect the longevity of infused donor cells and predict effectiveness of treatment. This study measure DNA of donor cells will in patients blood at the end of protocol. Absence of donor DNA suggest no chimerism.
Time Frame
6 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Confirmed diagnosis: Cerebral Palsy. Exclusion Criteria: the presence of the following diseases in history: heart failure in the stage of decompensation, stroke in history less than 1 year ago, blood diseases; decompensation of chronic and endocrinological diseases; acute respiratory viral and bacterial infections, period less than 1 month after the acute phase. HIV infection, hepatitis B and C. oncological diseases, chemotherapy in the anamnesis; tuberculosis.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
STANISLAV VOLCHKOV, MD, PhD
Phone
+79608159408
Email
bioen07@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Olga Tyumina, M.D, PhD
Email
centr123@bk.ru
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
STANISLAV VOLCHKOV, MD, PhD
Organizational Affiliation
Medical Centre Dinasty
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical Centre Dinasty
City
Samara
ZIP/Postal Code
443095
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stanislav Volchkov, MD
Phone
+78469564455
Email
quality@cordbank.ru
First Name & Middle Initial & Last Name & Degree
Pavel Ovchinnikov, MD
Phone
+78469564455
First Name & Middle Initial & Last Name & Degree
Stanislav Volchkov
First Name & Middle Initial & Last Name & Degree
Pavel Ovchinnikov
First Name & Middle Initial & Last Name & Degree
Alexander Bugakov

12. IPD Sharing Statement

Learn more about this trial

Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy

We'll reach out to this number within 24 hrs